Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ObsEva SA (OBSV : NSDQ)

• Company Description    ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. Number of Employees: 51

• Price / Volume Information    Yesterday's Closing Price: $1.74 Daily Weekly Monthly 20 Day Moving Average: 566,878 shares Shares Outstanding: 77.97 (millions) Market Capitalization: $135.67 (millions) Beta: 0.67 52 Week High: $3.58 52 Week Low: $1.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 23.40% 38.98% 12 Week 31.82% 44.91% Year To Date -12.56% 2.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Chemin des Aulx 12 Plan-les-Ouates - Geneva,V8 1228 CHE ph: 41-22-552-3840 fax: - ir@obseva.ch http://www.obseva.com

• General Corporate Information    Officers Brian O'Callaghan - Chief Executive Officer and Director Frank Verwiel - Chairperson of the Board of Directors Will Brown - Chief Financial Officer Clive Bertram - Chief Commercial Officer Ernest Loumaye - Director Peer Information ObsEva SA (CORR.) ObsEva SA (RSPI) ObsEva SA (CGXP) ObsEva SA (BGEN) ObsEva SA (GTBP) ObsEva SA (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5861P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 77.97 Most Recent Split Date: (:1) Beta: 0.67 Market Capitalization: $135.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 51.72% vs. Previous Quarter: 46.15% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -137.37 12/31/21 - -139.32 09/30/21 - -158.43 ROA 03/31/22 - -54.10 12/31/21 - -60.96 09/30/21 - -63.28 Current Ratio 03/31/22 - 3.09 12/31/21 - 2.70 09/30/21 - 3.84 Quick Ratio 03/31/22 - - 12/31/21 - 2.70 09/30/21 - 3.84 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -2,232.01 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.36 12/31/21 - 0.41 09/30/21 - 0.57 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 1.18 12/31/21 - 0.80 09/30/21 - 0.58 Debt-to-Capital 03/31/22 - 54.23 12/31/21 - 44.31 09/30/21 - 36.71

Powered by Zacks Investment Research ©